Albany Molecular Research Overview
Albany Molecular Research (AMRI) has a ROE of -18.85%, below the sector sector average of 11.73%.
Get informed when a big investor buys or sells
+ Follow-18.85%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Albany Molecular Research's return on equity stands at -18.85%. That is below the sector sector average of 11.73%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Albany Molecular Research sits lower the its sector benchmark (11.73%) with a ROE of -18.85%. That is roughly 260.7% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of -18.85% for Albany Molecular Research means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Albany Molecular Research's ROE evolved across reporting periods, while the comparison chart places AMRI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
